NCT04432155View on ClinicalTrials.gov

Xenon Inhalation for Treatment of Panic Disorder

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

December 31, 2021

Conditions
Panic Disorder
Interventions
DRUG

Xenon

30% xenon, 30% oxygen, and 40% nitrogen

DRUG

Placebo

30% oxygen, and 70% nitrogen

Sponsors
All Listed Sponsors
lead

Nobilis Therapeutics Inc.

INDUSTRY

NCT04432155 - Xenon Inhalation for Treatment of Panic Disorder | Biotech Hunter | Biotech Hunter